Yarbrough Capital’s Axsome Therapeutics AXSM Stock Holding History

Yarbrough Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Buy	+842	New	+$183K	0.01%	87
2026 Q1	–	Sell	-5,054	Closed	-$923K	–	95
2025 Q4	$923K	Hold	5,054	–	–	0.03%	91
2025 Q3	$614K	Hold	5,054	–	–	0.02%	112
2025 Q2	$528K	Hold	5,054	–	–	0.02%	125
2025 Q1	$589K	Hold	5,054	–	–	0.03%	125
2024 Q4	$428K	Hold	5,054	–	–	0.02%	137
2024 Q3	$454K	Hold	5,054	–	–	0.02%	142
2024 Q2	$407K	Hold	5,054	–	–	0.02%	145
2024 Q1	$403K	Buy	+5,054	New	+$424K	0.02%	152

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Yarbrough Capital's AXSM Position: Q2 2026 in Review

Yarbrough Capital opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 842 shares worth $206K. The stake represents 0.01% of the portfolio and ranks #87 among its holdings. This is a return to the name: Yarbrough Capital previously reported a position in AXSM as recently as Q4 2025.

Yarbrough Capital first reported a position in AXSM in Q1 2024 and has held it in 9 quarters since. The position peaked at $923K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Yarbrough Capital held 842 shares of Axsome Therapeutics worth $206K as of Q2 2026.
Axsome Therapeutics was a new Yarbrough Capital position in Q2 2026.
Axsome Therapeutics made up 0.01% of Yarbrough Capital's portfolio in Q2 2026, its #87 holding.
Yarbrough Capital first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 9 quarters since.
Yarbrough Capital's Axsome Therapeutics position peaked at $923K in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Yarbrough Capital's 13F filing for Q2 2026, filed 11 Aug 2026.